WO2025172762 - NANODRUG PRODUCT WITH CONTROLLED RELEASE OF HOCL AT TUMOR SITE FOR LUNG CANCER TREATMENT
National phase entry is expected:
Publication Number
WO/2025/172762
Publication Date
21.08.2025
International Application No.
PCT/IB2024/063181
International Filing Date
26.12.2024
Title **
[English]
NANODRUG PRODUCT WITH CONTROLLED RELEASE OF HOCL AT TUMOR SITE FOR LUNG CANCER TREATMENT
[French]
NANOMÉDICAMENT À LIBÉRATION CONTRÔLÉE DE HOCL AU NIVEAU D'UN SITE TUMORAL POUR LE TRAITEMENT DU CANCER DU POUMON
Applicants **
SHABANI, Shahrzad
Inventors
SHABANI, Shahrzad
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1889 | |
| EPO | Filing, Examination, Granting | 8796 | |
| Japan | Filing, Examination, Granting | 2065 | |
| South Korea | Filing, Examination, Granting | 1732 | |
| USA | Filing, Examination, Granting | 8940 |
Total:
23,422
Contact Us
Abstract[English]
This invention introduces a method of development for a nanodrug that releases HOCl at tumor sites for treating lung cancer. The process involves creating alginate chitosan nanoparticles, measuring folate conjugation to chitosan, studying the properties of the nanoparticles, assessing HOCl release and cytotoxicity, and evaluating the impact on cancer cells by analyzing protein expression. Additionally, the penetration and effects of the nanoparticles are studied in a mouse model of lung cancer to understand their behavior in vivo. Overall, this patent aims to develop a targeted and effective treatment for lung cancer with minimal side effects on healthy tissues.[French]
La présente invention concerne un procédé de développement d'un nanomédicament qui libère du HOCl au niveau de sites tumoraux pour le traitement du cancer du poumon. Le procédé consiste à créer des nanoparticules d'alginate de chitosane, mesurer la conjugaison du folate au chitosane, étudier les propriétés des nanoparticules, évaluer la libération et la cytotoxicité du HOCl et évaluer l'impact sur les cellules cancéreuses en analysant l'expression protéique. De plus, la pénétration et les effets des nanoparticules sont étudiés sur un modèle murin du cancer du poumon pour comprendre leur comportement in vivo. Globalement, ce brevet vise à développer un traitement ciblé et efficace du cancer du poumon ayant des effets secondaires minimaux sur les tissus sains.